(N-(4-methylphenyl)-4-pyridin-2-yl-1,3-thiazol-2-amine) | 315702-77-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (N-(4-methylphenyl)-4-pyridin-2-yl-1,3-thiazol-2-amine)
• 英文别名: MMV007907；4-(pyridin-2-yl)-N-p-tolylthiazol-2-amine；N-(4-methylphenyl)-4-pyridin-2-yl-1,3-thiazol-2-amine
• CAS: 315702-77-3
• 化学式: C₁₅H₁₃N₃S
• mdl: MFCD01121979
• 分子量: 267.354
• InChiKey: XCRBIEGWIQBOCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-苯甲酰基-N'-(4-甲基苯基)硫脲 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 6.0h， 生成 (N-(4-methylphenyl)-4-pyridin-2-yl-1,3-thiazol-2-amine)
  参考文献：
  名称：

  Structure–activity relationships of 2-aminothiazoles effective against Mycobacterium tuberculosis

  摘要：

  A series of 2-aminothiazoles was synthesized based on a HTS scaffold from a whole-cell screen against Mycobacterium tuberculosis (Mtb). The SAR shows the central thiazole moiety and the 2-pyridyl moiety at C-4 of the thiazole are intolerant to modification. However, the N-2 position of the aminothiazole exhibits high flexibility and we successfully improved the antitubercular activity of the initial hit by more than 128-fold through introduction of substituted benzoyl groups at this position. N-(3-Chlorobenzoyl)-4-(2-pyridinyl)-1,3-thiazol-2-amine (55) emerged as one of the most promising analogues with a MIC of 0.024 mu M or 0.008 mu g/mL in 7H9 media and therapeutic index of nearly similar to 300. However, 55 is rapidly metabolized by human liver microsomes (t(1/2) = 28 min) with metabolism occurring at the invariant aminothiazole moiety and Mtb develops spontaneous low-level resistance with a frequency of similar to 10 (5). (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.08.048

文献信息

• Anti-fungal inhibitors
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US11246857B2

  公开（公告）日：2022-02-15

  Described herein are methods of treating or preventing a fungal infection by administering one or more compounds of the present invention to a subject. The methods of the present invention treat or prevent a fungal infection of C. neoformans, C. gattii, L. prolificans, C. albicans, or a combination thereof, as examples. The compounds of the present invention may be administered to a subject with other agents such as antifungal agents.

  本文描述了通过向受试者施用一种或多种本发明化合物来治疗或预防真菌感染的方法。例如，本发明的方法可治疗或预防新变形真菌、加特氏真菌、增殖真菌、白僵菌或其组合的真菌感染。本发明的化合物可与其他制剂如抗真菌制剂一起施用给受试者。
• MAMMALIAN HEDGEHOG SIGNALING MODULATORS
  申请人：Oinas Antti

  公开号：US20090156611A1

  公开（公告）日：2009-06-18

  The disclosure relates to compositions for and methods of inhibiting the mammalian Hedgehog signaling pathway.
• IDENTIFICATION OF COMPOUNDS WHICH INHIBIT ATG8-ATG3 PROTEIN-PROTEIN INTERACTION AND THEIR USE AS ANTIPARASITICAL AGENTS
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20170044150A1

  公开（公告）日：2017-02-16

  The present invention provides compounds or a pharmaceutically acceptable salts, solvates, stereoisomers, or prodrugs thereof which can block the Atg8-Atg3 protein-protein interaction, which is associated with autophagy in apicomplexan organisms. Pharmaceutical compositions comprising these compounds and their use for the suppression and treatment of various parasitical diseases are also provided.
• METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE
  申请人：Design Therapeutics, Inc.

  公开号：US20210238226A1

  公开（公告）日：2021-08-05

  The present disclosure relates to compounds and methods for modulating the expression of dmpk, atxn1, atxn2, atxn3, cacna1a, atxn7, ppp2r2br tbp, htt, jph3r ar, or atn1 and treating diseases and conditions in which dmpk, atxn1, atxn2, atxn3, cacna1a, atxn1, ppp2r2b, tbp, htt, jph3, ar, or atn1 plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.
• [EN] MAMMALIAN HEDGEHOG SIGNALING INHIABITORS<br/>[FR] INHIBITEURS DE SIGNALISATION DU HERISSON DES MAMMIFERES
  申请人：LICENTIA OY

  公开号：WO2007054623A2

  公开（公告）日：2007-05-18

  [EN] (The disclosure relates to compositions for and methods of inhibiting the mammalian Hedgehog signaling pathway.
  [FR] La présente invention concerne des compositions et des procédés permettant d'inhiber la voie de signalisation du hérisson des mammifères.